The GTPBP3 Knockout A-549 Polyclonal Cells product consists of a heterogeneous population of A-549 cells with CRISPR/Cas9-mediated disruption of the GTPBP3 gene. This polyclonal knockout model enables loss-of-function studies of mitochondrial tRNA modification in a lung adenocarcinoma background. By providing a pooled gene-edited population, it captures diverse mutational events and avoids clonal artifacts. The product is designed for advanced biomedical research on mitochondrial translation, cancer metabolism, and related disorders.
The A-549 host cell line, derived from human lung adenocarcinoma, serves as an established model of alveolar type II epithelial cells. It is widely used in lung cancer biology, drug metabolism, and toxicological studies. These cells exhibit mitochondrial metabolism that is highly relevant to investigating metabolic reprogramming in non-small cell lung cancer. The knockout of GTPBP3 in A-549 cells therefore provides a clinically pertinent platform for probing mitochondrial dysfunction within the context of oncogenic transformation.
GTPBP3 is a GTP-binding enzyme that, together with MTO1, catalyzes 5-taurinomethyluridine (??m5U) modification at the wobble position of mitochondrial tRNAs (MT-TL1, MT-TK, MT-TE, MT-TQ). This modification ensures accurate mitochondrial translation of mtDNA-encoded subunits, including MT-CO1, MT-ND1, and MT-CYB, which are integral to respiratory chain complexes. Disruption of GTPBP3 activity impairs mitochondrial protein synthesis, leading to defective oxidative phosphorylation and energy metabolism. The protein is functionally linked to mitochondrial biogenesis pathways but has no well-characterized upstream regulators.
In A-549 cells, GTPBP3 deletion compromises mitochondrial translation, thereby reducing oxidative phosphorylation and potentially inducing a glycolytic shift characteristic of cancer metabolism. This model allows direct investigation of mitochondrial deficiencies associated with combined oxidative phosphorylation deficiency 23, mitochondrial encephalomyopathy, hypertrophic cardiomyopathy, and lactic acidosis. The polyclonal nature recapitulates the spectrum of loss-of-function mutations, offering a more representative system for translational research than single-cell clones.
This knockout cell pool is suitable for western blotting of mtDNA-encoded proteins, RT-qPCR detection of mitochondrial RNAs, and Seahorse assays measuring oxygen consumption and extracellular acidification. ATP and cell proliferation measurements help quantify metabolic changes, while drug sensitivity testing identifies therapeutic vulnerabilities. tRNA modification profiling by LC-MS permits direct assessment of ??m5U levels. Applications include mitochondrial disease modeling, oxidative phosphorylation analysis, cancer metabolism investigation, and drug discovery. For additional information, please contact Ascent Research.
